Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 0 | 0 | 0 | 192 | 249 |
| Cost of Goods | N/A | N/A | N/A | 85 | -714 |
| Gross Profit | N/A | N/A | N/A | 107 | 963 |
| Operating Expenses | 19,198 | 19,316 | 14,669 | 13,501 | 13,110 |
| Operating Income | -19,198 | -19,316 | -14,669 | -13,309 | -12,861 |
| Other Income | -11,416 | -1,433 | 1,528 | -21,916 | 35,884 |
| Pre-tax Income | -30,614 | -20,749 | -13,141 | -35,225 | 23,023 |
| Income Tax | 11 | 16 | 8 | 114 | -14 |
| Net Income Continuous | -30,625 | -20,765 | -13,149 | -35,339 | 23,037 |
| Net Income | $-30,625 | $-20,765 | $-13,149 | $-35,339 | $23,037 |
| EPS Basic Total Ops | -2.19 | -1.92 | -1.25 | 128.01 | 0.98 |
| EPS Basic Continuous Ops | -2.19 | -1.92 | -1.25 | 33.83 | 4.15 |
| EPS Diluted Total Ops | -2.19 | -1.92 | -1.25 | 137.13 | -2.83 |
| EPS Diluted Continuous Ops | -2.19 | -1.92 | -1.25 | 121.45 | 2.14 |
| EPS Diluted Before Non-Recurring Items | -2.19 | -1.92 | -1.25 | N/A | -2.83 |
| EBITDA(a) | $-19,139 | $-19,182 | $-14,534 | $-13,241 | $-12,827 |